Addex Therapeutics Ltd (ADR) ( (ADXN) ) has released its Q2 earnings. Here is a breakdown of the information Addex Therapeutics Ltd (ADR) presented to its investors.Elevate Your Investing Strategy: Take...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 26, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company...
CHF14.9M ($16.1M) of cash and cash equivalents at March 31, 2022Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022Phase...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 31, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are scheduled...
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual...